DESCRIPTION:
Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis agents, antitumor vaccines, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents.
Features:
Summarizes the current and ongoing efforts in the development of new anticancer drugs with perspective and vision for the future directions of research in the field of biomedical science.
CONTENTS:
1. Cancer Drug Discovery and Development: New Paradigms for a New Millennium
2. Evolutionary Biosynthesis of Anticancer Drugs
3. Some Recent Developments in the Synthesis and SAR of Novel Taxanes
4. New Generation Taxoids and Hybrids of Microtube-Stabilizing Anticancer Agents
5. Discodermolide and Taxol: A Synergistic Drug Combination in Human Carcinoma Cell Lines
6. Highly Efficient Semisynthesis of Biologically Active Epothilone Derivatives
7. Synthetic and Semisynthetic Analogs of Epothilones: Chemistry and Biological Activity
8. Synthesis and Biological Activity of Epothilones
9. Epothelones and Sarcodictyins: From Combinatorial to Designed Analogs
10. Synthesis and Structure-Activity Relationship Studies of Cryptophycins: A Novel Class of Potent Antimitotic Tumor Depsipeptides
11. Farnesyltransferase Inhibitors as Potential Anticancer Agents
12. Farnesyltransferase Inhibitors: From Squalene Synthase Inhibitors to the Clinical Agent BMS-214662
13. Inhibiting Farnesyl Protein Transferase with Sch-66336: Potentially a Selective Non-Cytotoxic herapy for Human Cancer
14. Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase
15. STI571: A New Treatment Modality for CML
16. The Discovery and Development of Second-Generation Matrix Metalloproteinase Inhibitors for the Treatment of Cancer
17. Prospects for Anti-Angiogenic Therapies Based upon VEGF Inhibition
18. Carbohydrate-Based Tumor Antigens as Anti-Tumor Vaccine Agents
19. Drugs to Enhance the Therapeutic Potency of Anti-Cancer Antibodies
